These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 32803316)
1. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. Guo F; Song X; Li Y; Guan W; Pan W; Yu W; Li T; Hsieh E Osteoporos Int; 2021 Feb; 32(2):321-332. PubMed ID: 32803316 [TBL] [Abstract][Full Text] [Related]
2. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males. Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320 [TBL] [Abstract][Full Text] [Related]
3. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study. Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P; PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458 [TBL] [Abstract][Full Text] [Related]
4. Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals. Guan W; Pan W; Yu W; Cao W; Lin Q; Zhang Z; Song X; Li Y; Tian J; Xu Y; Li T; Hsieh E Arch Osteoporos; 2021 Feb; 16(1):41. PubMed ID: 33624129 [TBL] [Abstract][Full Text] [Related]
5. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda. Kiweewa Matovu F; Kiwanuka N; Nabwana M; Scholes D; Musoke P; Glenn Fowler M; Beksinska ME; Pettifor JM; Brown TT; Lancet Glob Health; 2022 May; 10(5):e694-e704. PubMed ID: 35427526 [TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV. Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A; AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785 [TBL] [Abstract][Full Text] [Related]
7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863 [TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537 [TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923 [TBL] [Abstract][Full Text] [Related]
10. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM; Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682 [TBL] [Abstract][Full Text] [Related]
11. The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study. Alvarez E; Campbell L; Tinago W; Garcia-Leon A; Walsh I; Brady JJ; Burling K; Noe S; Neuville MF; Jouret F; Jamshidian F; Graham H; Rhee M; Mallon PW; Post FA Antivir Ther; 2022 Aug; 27(4):13596535221094898. PubMed ID: 36000318 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial. Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840 [TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. Liu AY; Vittinghoff E; Sellmeyer DE; Irvin R; Mulligan K; Mayer K; Thompson M; Grant R; Pathak S; O'Hara B; Gvetadze R; Chillag K; Grohskopf L; Buchbinder SP PLoS One; 2011; 6(8):e23688. PubMed ID: 21897852 [TBL] [Abstract][Full Text] [Related]
14. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study. Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910 [TBL] [Abstract][Full Text] [Related]
15. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW; J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922 [TBL] [Abstract][Full Text] [Related]
16. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR; Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069 [TBL] [Abstract][Full Text] [Related]
17. Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy. Guan WM; Pan W; Yu W; Cao W; Lin Q; Zhang ZZ; Song XJ; Li YL; Tian JP; Xu Y; Li TS; Hsieh E J Orthop Translat; 2021 Jul; 29():72-77. PubMed ID: 34094860 [TBL] [Abstract][Full Text] [Related]
18. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995 [TBL] [Abstract][Full Text] [Related]
19. Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients. Hamzah L; Samarawickrama A; Campbell L; Pope M; Burling K; Fisher M; Gilleece Y; Walker-Bone K; Post FA AIDS; 2015 Sep; 29(14):1785-1792. PubMed ID: 26372384 [TBL] [Abstract][Full Text] [Related]
20. Prevalence and associated factors of low bone mineral density in people living with HIV: a cross-sectional study. Shao Y; Sun J; Kong K; Zhang R; Zhang R; Liu L; Wang J; Shen Y; Wu L; Zheng Z; Sun M; Qi T; Wang Z; Tang Y; Sun J; Song W; Yang J; Xu S; Zhao B; Shan F; Qin A; Lu H; Chen J Arch Osteoporos; 2024 Jul; 19(1):56. PubMed ID: 38954143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]